Mather Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Mather Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-65	Closed	-$2.82K	–	2111
2024 Q2	$2.82K	Buy	+65	New	+$2.6K	﹤0.01%	1792

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mather Group's RYTM Position: Q3 2024 in Review

Mather Group sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2024, closing a stake of 65 shares — an estimated $2.82K sold.

Mather Group first reported a position in RYTM in Q2 2024 and held it in 1 quarter. The position peaked at $2.82K in Q2 2024. 176 funds tracked by Wall St. Rank hold RYTM as of Q3 2024.

Mather Group reported no remaining Rhythm Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Mather Group sold 65 Rhythm Pharmaceuticals shares in Q3 2024, an estimated $2.82K.
Mather Group first reported a position in Rhythm Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Mather Group's Rhythm Pharmaceuticals position peaked at $2.82K in Q2 2024.
176 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.